The DEA’s decision to reclassify cannabis from Schedule I to Schedule III has significant implications. This acknowledges cannabis’ medicinal value and could lead to increased access to medical cannabis. The move could also benefit the cannabis industry financially and have a positive impact on other controlled substances. However, it does not fully address conflicts between state and federal law, leaving consumers vulnerable to federal prosecution. Ultimately, Congress needs to take responsibility for comprehensive drug reform.
Read the full story here
Written by: Michelle Minton, opinion contributor
Published on May 6, 2024 at 05:09AM
Source: Just In News | The Hill (opens in new tab)